查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
脂质奈米颗粒市场：按产品、按 LNP 类型、按分子类型、按应用、按最终用户、按服务类型、按地区 - 预测到 2029 年
市场调查报告书
商品编码
1558957

脂质奈米颗粒市场：按产品、按 LNP 类型、按分子类型、按应用、按最终用户、按服务类型、按地区 - 预测到 2029 年

Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 317 Pages | 订单完成后即时交付

价格

全球脂质奈米粒子（LNPs）市场规模预计将从2024年的2.718亿美元增加至2029年的3.505亿美元，2024年至2029年的复合年增长率为5.2%。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
考虑单位 金额（美元）
按细分市场 按产品、按 LNP 类型、按分子类型、按应用、按最终用户、按服务类型、按地区
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东/非洲

全球脂质奈米颗粒服务市场规模预计在 2024 年达到 1.355 亿美元，2029 年达到 2.381 亿美元，2024-2029 年预测期间复合年增长率为 11.9%。

脂质奈米颗粒市场的成长主要是由公司越来越多地将脂质奈米颗粒用于 RNA 疗法、个人化医疗、肿瘤学和其他治疗方法的药物开发所推动的。作为注射疗法的新赋形剂，监管部门的核准有限，因此，脂质奈米颗粒製造没有既定的监管流程，可能会阻碍市场的成长。

COVID-19下的商业应用领域是2023年在全球脂质奈米颗粒市场中占有最高份额的领域。由于脂质奈米颗粒 (LNP) 能够提高 mRNA 的稳定性和可用性，因此在基于 mRNA 的 COVID-19 疫苗中使用脂质奈米颗粒 (LNP) 是建立该市场的驱动因素之一。随着COVID-19疫苗接种量的下降，用于肿瘤学和其他适应症的RNA疗法和基于LNP的药物的开发等临床应用预计将推动该市场的成长。

该报告研究了全球脂质奈米颗粒市场，包括按 LNP 类型、分子类型、应用、最终用户、服务类型、区域和进入市场的公司概况分類的趋势。

目录

第一章简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 介绍
  • 市场动态
  • 影响客户业务的趋势/干扰
  • 价格分析
  • 供应链分析
  • 价值链分析
  • 生态系分析
  • 技术分析
  • 专利分析
  • 2024-2025年重大会议和活动
  • 监管状况
  • 波特五力分析
  • 主要相关人员和采购标准
  • 主要采购标准
  • 投资金筹措场景
  • 生成式人工智慧对 LNP 原料与服务市场的影响

第六章 LNP原料市场（分产品）

  • 介绍
  • 离子化脂质
  • 聚乙二醇化脂质
  • 中性脂质
  • 磷脂
  • 试剂套件和试剂
  • 其他的

第七章 LNP原料市场（依LNP类型）

  • 介绍
  • 固体脂质奈米颗粒（SLNS）
  • 奈米结构脂质载体（NLCS）
  • 其他的

第八章 LNP原料市场（依分子类型）

  • 介绍
  • siRNA
  • RNA
  • 其他的

第九章 LNP原料市场（依用途）

  • 介绍
  • 商业的
  • 临床应用

第10章 LNP原料市场（依最终用户）

  • 介绍
  • 製药和生物技术公司
  • 学术研究所
  • 合约开发和製造组织（CDMOS）

第十一章 LNP服务市场（依服务类型）

  • 介绍
  • 处方开发服务
  • 製造服务
  • 其他的

第十二章 LNP服务市场（依最终用户）

  • 介绍
  • 製药和生物技术公司
  • 学术研究所

第十三章 LNP原料与服务市场（分地区）

  • 介绍
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东
  • 非洲

第14章竞争格局

  • 介绍
  • 主要参与企业的策略/秘密
  • 收益分析
  • 市场占有率分析
  • 企业评估矩阵：主要参与企业，2023
  • 企业评估矩阵：Start-Ups/小型企业，2023 年
  • 公司评价及财务指标
  • 品牌/产品比较分析
  • 竞争场景

第十五章 公司简介

  • 主要参与企业
    • AVANTI POLAR LIPIDS（CRODA INTERNATIONAL PLC）
    • MERCK KGAA
    • EVONIK INDUSTRIES AG
    • NIPPON FINE CHEMICAL
    • NOF CORPORATION
    • FUJIFILM PHARMACEUTICALS USA, INC.（FUJIFILM HOLDINGS CORPORATION）
    • PRECISION NANOSYSTEMS（CYTIVA）
    • RECIPHARM AB
    • EMERGENT
    • EUROAPI
    • CAYMAN CHEMICAL
    • CORDENPHARMA
    • GATTEFOSSE
    • ACUITAS THERAPEUTICS
    • IOI OLEO GMBH
  • 其他公司
    • CREATIVE BIOLABS
    • CURAPATH
    • LIPOID GMBH
    • NANOCS INC.
    • MEDKOO BIOSCIENCES, INC.
    • POLYSCIENCES INC.
    • BIOVECTRA
    • ASCENDIA PHARMACEUTICALS
    • CURIA GLOBAL, INC.
    • VERNAL BIOSCIENCES

第十六章附录

Product Code: BT 9141

The global lipid nanoparticles market is expected to reach USD 350.5 million by 2029, from USD 271.8 million in 2024, at a CAGR of 5.2% from 2024 to 2029.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsBy Product, LNP Type, Molecule Type, Application, End User, Service Type, End User (Services)
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

The global lipid nanoparticles services market is projected to reach USD 135.5 million in 2024 to USD 238.1 million in 2029, at a CAGR of 11.9% of during the forecast period of 2024 to 2029.

The growth of the lipid nanoparticles market has been significantly driven by the increasing use of lipid nanoparticles by players for the drug development of RNA therapeutics, personalized medicine, oncology & other therapies. Being a novel excipient for injectable therapies, limited regulatory approvals and resulting lack of established regulatory processes for lipid nanoparticle production are likely to deter the growth of the market.

" The Covid-19 commercial application segment was the highest share holding segment by application in 2023."

The commercial application segment under Covid-19 was the highest share holding segment in 2023 in the global lipid nanoparticles market. Lipid nanoparticles (LNP) usage in mRNA based COVID-19 vaccines due to their ability to enhance the stability and availability of mRNA was one of the drivers for establishing this market. With the decline in COVID-19 vaccinations, it is expected that clinical applications such as development of RNA therapeutics & LNP based drugs for oncology and other indications will drive the growth in this market.

"The US has continued to dominate the lipid nanoparticles market during the forecast period of 2024-2029."

Two main mRNA-based COVID-19 vaccine producers that have shown success are Pfizer-BioNTech and Moderna, who have generated billions of doses together. With US government initiative such as Operation Warp Speed, US based biopharmaceutical companies have developed signicant capacities for RNA & LNP production as well as capabilities for development of LNP based drugs. Established LNP & RNA ecosystem and drug development activities from pharmaceutical & biotech companies as well as CDMOs are expected to help the US market retain its leadership in lipid nanoparticles development & manufacturing.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70% and Demand Side 30%
  • By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

Avanti Polar Lipids (Croda International plc) (US)

Merck KGaA (Germany)

Evonik Industries AG (Germany)

IOI Oleo Gmbh (Germany)

FUJIFILM Pharmaceuticals U.S.A., Inc. (US)

Nippon Fine Chemical (Japan)

Recipharm AB (Sweden)

Emergent (US)

EUROAPI (France)

Cayman Chemical (US)

CordenPharma (Switzerland)

NOF CORPOTATION (Japan)

Precision NanoSystems (Canada)

Gattefosse (France)

Acuitas Therapeutics (Canada)

Creative Biolabs (US)

Curapath (Spain)

Lipoid Gmbh (Germany)

Nanocs, Inc. (US)

MedKoo Biosciences, Inc. (US)

Polysciences, Inc. (US)

BIOVECTRA (Canada)

Ascendia Pharmaceuticals (US)

Curia Global, Inc. (US)

Vernal Biosciences (US)

Research Coverage:

This research report categorizes the lipid nanoparticles market by product (ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials), by LNP type (solid lipid nanoparticles, nanostructured lipid carriers, and other types), by molecule type (si RNA, m RNA, and other molecules), by application ((commercial (Polyneuropathy, Covid-19), clinical (Covid-19, cancer, other diseases)), by end user (pharmaceutical & biotechnologies companies, CDMO's, academic & research institutes), by service type (formulation development services, manufacturing services, and other services), by end user of services (pharmaceutical & biotechnologies companies, academic & research institutes), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the lipid nanoparticles market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, services, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the lipid nanoparticles market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall lipid nanoparticles market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing use of lipid nanoparticles in anti-cancer therapies, Increasing use of lipid nanoparticles in RNA-based therapies, Growing government focus on R&D of key players for the development of lipid nanoparticles-based drugs, restraints (Stringent regulations associated lipid nanoparticles, High cost and difficulties for production of lipid nanoparticles), opportunities (Growing demand for advanced drug delivery systems), and Challenges (Formulation related challenges).
  • Product Development/Innovation: Detailed insights on newly launched products/services of the lipid nanoparticles market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
  • Market Diversification: Exhaustive information about new products, new services, untapped geographies, recent developments, and investments in the lipid nanoparticles market
  • Competitive Assessment: Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), IOI Oleo GmbH (Germany), among others in the market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
    • 1.5.1 VALUE UNIT
  • 1.6 MARKET STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.2 INSIGHTS OF PRIMARY EXPERTS
  • 2.3 MARKET GROWTH RATE PROJECTIONS
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: LNP RAW MATERIALS & SERVICES MARKET, BY PRODUCT
  • 4.3 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 LNP RAW MATERIALS MARKET, BY END USER, 2023
  • 4.5 LNP SERVICES MARKET, BY END USER, 2023

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing use of lipid nanoparticles in anti-cancer research
      • 5.2.1.2 High uptake in RNA-based therapeutic research
      • 5.2.1.3 Growing government focus on R&D for LNP-based drugs
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent regulatory requirements
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing demand for advanced drug delivery systems
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Challenges associated with LNP formulation
    • 5.2.5 INDUSTRY TRENDS
      • 5.2.5.1 Growing preference for personalized medicine and targeted drug delivery
      • 5.2.5.2 Advancements in mRNA-based vaccine technology
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 INDICATIVE SELLING PRICE OF LNP PRODUCTS, BY KEY PLAYER
    • 5.4.2 INDICATIVE SELLING PRICE, BY PRODUCT
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 LNP RAW MATERIALS & SERVICES MARKET: ROLE IN ECOSYSTEM
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 Nanotechnology-based drug delivery
      • 5.8.1.2 Nucleic acid delivery
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Drug encapsulation techniques
      • 5.8.2.2 Surface modification and functionalization technologies
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Biotechnology & genetic engineering technologies
      • 5.8.3.2 Nanotechnology-based formulation techniques
  • 5.9 PATENT ANALYSIS
    • 5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014-2023
    • 5.9.2 INNOVATION AND PATENT APPLICATIONS
    • 5.9.3 TOP APPLICANTS
  • 5.10 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.11 REGULATORY LANDSCAPE
    • 5.11.1 REGULATORY SCENARIO
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 DEGREE OF COMPETITION
    • 5.12.2 BARGAINING POWER OF SUPPLIERS
    • 5.12.3 BARGAINING POWER OF BUYERS
    • 5.12.4 THREAT OF SUBSTITUTES
    • 5.12.5 THREAT OF NEW ENTRANTS
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIPID NANOPARTICLES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 5.14 KEY BUYING CRITERIA
    • 5.14.1 BUYING CRITERIA FOR LNP RAW MATERIALS
    • 5.14.2 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
    • 5.14.3 BUYING CRITERIA FOR LNP SERVICES
    • 5.14.4 BUYING CRITERIA FOR LNP SERVICES, BY END USER
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 IMPACT OF GENERATIVE AI ON LNP RAW MATERIALS & SERVICES MARKET

6 LNP RAW MATERIALS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 IONIZABLE LIPIDS
    • 6.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET
  • 6.3 PEGYLATED LIPIDS
    • 6.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND
  • 6.4 NEUTRAL LIPIDS
    • 6.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
  • 6.5 PHOSPHOLIPIDS
    • 6.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH
  • 6.6 KITS & REAGENTS
    • 6.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET
  • 6.7 OTHER FORMULATION MATERIALS

7 LNP RAW MATERIALS MARKET, BY LNP TYPE

  • 7.1 INTRODUCTION
  • 7.2 SOLID LIPID NANOPARTICLES (SLNS)
    • 7.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET
  • 7.3 NANOSTRUCTURED LIPID CARRIERS (NLCS)
    • 7.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET
  • 7.4 OTHER LNP TYPES

8 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE

  • 8.1 INTRODUCTION
  • 8.2 SIRNA
    • 8.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET
  • 8.3 MRNA
    • 8.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET
  • 8.4 OTHER MOLECULES

9 LNP RAW MATERIALS MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 COMMERCIAL APPLICATIONS
    • 9.2.1 POLYNEUROPATHY
      • 9.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand
    • 9.2.2 COVID-19
      • 9.2.2.1 Enhanced stability and distribution of mRNA to drive market
  • 9.3 CLINICAL APPLICATIONS
    • 9.3.1 COVID-19
      • 9.3.1.1 Threat of evolving emerging variants to fuel uptake
    • 9.3.2 CANCER
      • 9.3.2.1 Increasing focus on oncology therapeutics to drive market
    • 9.3.3 OTHER CLINICAL APPLICATIONS

10 LNP RAW MATERIALS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET
  • 10.3 ACADEMIC & RESEARCH INSTITUTES
    • 10.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET
  • 10.4 CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS)
    • 10.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET

11 LNP SERVICES MARKET, BY SERVICE TYPE

  • 11.1 INTRODUCTION
  • 11.2 FORMULATION DEVELOPMENT SERVICES
    • 11.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET
  • 11.3 MANUFACTURING SERVICES
    • 11.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET
  • 11.4 OTHER SERVICES

12 LNP SERVICES MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 12.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET
  • 12.3 ACADEMIC & RESEARCH INSTITUTES
    • 12.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH

13 LNP RAW MATERIALS & SERVICES MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 13.2.2 US
      • 13.2.2.1 High pharmaceutical R&D expenditure to drive market
    • 13.2.3 CANADA
      • 13.2.3.1 Growing focus on personalized medicine to drive market
  • 13.3 EUROPE
    • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 13.3.2 GERMANY
      • 13.3.2.1 Rising development activities for LNP production to drive market
    • 13.3.3 UK
      • 13.3.3.1 Pioneering research programs for drug delivery systems to boost demand
    • 13.3.4 FRANCE
      • 13.3.4.1 Government funding for proteomics and genomics research to support market growth
    • 13.3.5 ITALY
      • 13.3.5.1 Growth in life sciences research to propel market
    • 13.3.6 SPAIN
      • 13.3.6.1 Growing demand for cancer therapeutics to drive market
    • 13.3.7 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 13.4.2 CHINA
      • 13.4.2.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market
    • 13.4.3 JAPAN
      • 13.4.3.1 Demand for LNP-based mRNA vaccines to fuel market
    • 13.4.4 INDIA
      • 13.4.4.1 Growth in pharmaceutical industry to drive market
    • 13.4.5 SOUTH KOREA
      • 13.4.5.1 Rising number of clinical trials to boost demand
    • 13.4.6 AUSTRALIA
      • 13.4.6.1 Growing requirement for innovative drug delivery systems to propel market
    • 13.4.7 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 13.5.2 BRAZIL
      • 13.5.2.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake
    • 13.5.3 MEXICO
      • 13.5.3.1 Large target patient population and demand for novel drug delivery technology to drive market
    • 13.5.4 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST
    • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 13.6.2 GCC COUNTRIES
      • 13.6.2.1 Economic & healthcare expansion to support market growth
    • 13.6.3 REST OF MIDDLE EAST
  • 13.7 AFRICA
    • 13.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 14.3 REVENUE ANALYSIS
  • 14.4 MARKET SHARE ANALYSIS
    • 14.4.1 LNP SERVICES MARKET
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
    • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 14.5.5.1 Company footprint
      • 14.5.5.2 Product footprint
      • 14.5.5.3 Application footprint
      • 14.5.5.4 Service type footprint
      • 14.5.5.5 Region footprint
  • 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 RESPONSIVE COMPANIES
    • 14.6.3 DYNAMIC COMPANIES
    • 14.6.4 STARTING BLOCKS
    • 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 14.7 COMPANY VALUATION & FINANCIAL METRICS
    • 14.7.1 FINANCIAL METRICS
    • 14.7.2 COMPANY VALUATION
  • 14.8 BRAND/PRODUCT COMPARISON ANALYSIS
  • 14.9 COMPETITIVE SCENARIO
    • 14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 14.9.2 DEALS
    • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

  • 15.1 KEY PLAYERS
    • 15.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC)
      • 15.1.1.1 Business overview
      • 15.1.1.2 Products/Services offered
      • 15.1.1.3 Recent developments
        • 15.1.1.3.1 Deals
      • 15.1.1.4 MnM view
        • 15.1.1.4.1 Key strengths
        • 15.1.1.4.2 Strategic choices
        • 15.1.1.4.3 Weaknesses & competitive threats
    • 15.1.2 MERCK KGAA
      • 15.1.2.1 Business overview
      • 15.1.2.2 Products/Services offered
      • 15.1.2.3 Recent developments
        • 15.1.2.3.1 Deals
        • 15.1.2.3.2 Expansions
      • 15.1.2.4 MnM view
        • 15.1.2.4.1 Key strengths
        • 15.1.2.4.2 Strategic choices
        • 15.1.2.4.3 Weaknesses & competitive threats
    • 15.1.3 EVONIK INDUSTRIES AG
      • 15.1.3.1 Business overview
      • 15.1.3.2 Products/Services offered
      • 15.1.3.3 Recent developments
        • 15.1.3.3.1 Deals
      • 15.1.3.4 MnM view
        • 15.1.3.4.1 Key strengths
        • 15.1.3.4.2 Strategic choices
        • 15.1.3.4.3 Weaknesses & competitive threats
    • 15.1.4 NIPPON FINE CHEMICAL
      • 15.1.4.1 Business overview
      • 15.1.4.2 Products/Services offered
      • 15.1.4.3 MnM view
        • 15.1.4.3.1 Key strengths
        • 15.1.4.3.2 Strategic choices
        • 15.1.4.3.3 Weaknesses & competitive threats
    • 15.1.5 NOF CORPORATION
      • 15.1.5.1 Business overview
      • 15.1.5.2 Products/Services offered
      • 15.1.5.3 Recent developments
        • 15.1.5.3.1 Deals
      • 15.1.5.4 MnM view
        • 15.1.5.4.1 Key strengths
        • 15.1.5.4.2 Strategic choices
        • 15.1.5.4.3 Weaknesses & competitive threats
    • 15.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION)
      • 15.1.6.1 Business overview
      • 15.1.6.2 Products/Services offered
      • 15.1.6.3 Recent developments
        • 15.1.6.3.1 Expansions
    • 15.1.7 PRECISION NANOSYSTEMS (CYTIVA)
      • 15.1.7.1 Business overview
      • 15.1.7.2 Products/Services offered
      • 15.1.7.3 Recent developments
        • 15.1.7.3.1 Product/Service launches
        • 15.1.7.3.2 Deals
        • 15.1.7.3.3 Expansions
    • 15.1.8 RECIPHARM AB
      • 15.1.8.1 Business overview
      • 15.1.8.2 Products/Services offered
      • 15.1.8.3 Recent developments
        • 15.1.8.3.1 Deals
    • 15.1.9 EMERGENT
      • 15.1.9.1 Business overview
      • 15.1.9.2 Products/Services offered
      • 15.1.9.3 Recent developments
        • 15.1.9.3.1 Deals
    • 15.1.10 EUROAPI
      • 15.1.10.1 Business overview
      • 15.1.10.2 Products/Services offered
    • 15.1.11 CAYMAN CHEMICAL
      • 15.1.11.1 Business overview
      • 15.1.11.2 Products/Services offered
    • 15.1.12 CORDENPHARMA
      • 15.1.12.1 Business overview
      • 15.1.12.2 Products/Services offered
      • 15.1.12.3 Recent developments
        • 15.1.12.3.1 Product/Service launches
        • 15.1.12.3.2 Deals
        • 15.1.12.3.3 Expansions
    • 15.1.13 GATTEFOSSE
      • 15.1.13.1 Business overview
      • 15.1.13.2 Products/Services offered
    • 15.1.14 ACUITAS THERAPEUTICS
      • 15.1.14.1 Business overview
      • 15.1.14.2 Products/Services offered
      • 15.1.14.3 Recent developments
        • 15.1.14.3.1 Deals
    • 15.1.15 IOI OLEO GMBH
      • 15.1.15.1 Business overview
      • 15.1.15.2 Products/Services offered
  • 15.2 OTHER PLAYERS
    • 15.2.1 CREATIVE BIOLABS
    • 15.2.2 CURAPATH
    • 15.2.3 LIPOID GMBH
    • 15.2.4 NANOCS INC.
    • 15.2.5 MEDKOO BIOSCIENCES, INC.
    • 15.2.6 POLYSCIENCES INC.
    • 15.2.7 BIOVECTRA
    • 15.2.8 ASCENDIA PHARMACEUTICALS
    • 15.2.9 CURIA GLOBAL, INC.
    • 15.2.10 VERNAL BIOSCIENCES

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
  • TABLE 2 RISK ANALYSIS
  • TABLE 3 LNP RAW MATERIALS & SERVICES MARKET: IMPACT ANALYSIS
  • TABLE 4 INDICATIVE PRICING OF LNP PRODUCTS, BY KEY PLAYER
  • TABLE 5 INDICATIVE PRICING OF LNP PRODUCTS, BY TYPE
  • TABLE 6 PATENTS FILED, 2014-2023
  • TABLE 7 INDICATIVE LIST OF PATENTS IN LNP RAW MATERIALS & SERVICES MARKET
  • TABLE 8 LNP RAW MATERIALS & SERVICES MARKET: LIST OF CONFERENCES & EVENTS (2024-2025)
  • TABLE 9 REGULATORY SCENARIO
  • TABLE 10 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 LNP RAW MATERIALS & SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 16 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
  • TABLE 17 LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 18 IONIZABLE LIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 19 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 20 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 21 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 22 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 23 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 24 PEGYLATED LIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 25 NEUTRAL LIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 26 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 27 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 29 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 30 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 PHOSPHOLIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 36 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 37 KITS & REAGENTS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 38 OTHER FORMULATION MATERIALS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 40 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 EUROPE: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 45 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 52 OTHER LNP TYPES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 53 NORTH AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 54 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 ASIA PACIFIC: OTHER LNP TYPES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 LATIN AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 MIDDLE EAST: OTHER LNP TYPES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 59 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 62 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 70 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 71 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 72 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 77 LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 78 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 79 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 81 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 90 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 91 LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY REGION, 2022-2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 93 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 96 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY REGION, 2022-2029 (USD MILLION)
  • TABLE 97 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 98 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 100 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 101 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 102 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 103 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 104 LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY REGION, 2022-2029 (USD MILLION)
  • TABLE 105 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 106 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 108 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 109 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY REGION, 2022-2029 (USD MILLION)
  • TABLE 110 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 111 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 112 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 113 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 114 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 115 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 116 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 117 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 118 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 119 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 120 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 121 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 122 LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 123 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 124 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 125 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 128 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 129 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 131 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 134 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 135 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 140 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 141 LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 FORMULATION DEVELOPMENT SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 143 MANUFACTURING SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 144 OTHER SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 145 LNP SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 146 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 147 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 148 LNP RAW MATERIALS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 149 LNP SERVICES MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 150 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 151 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 152 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 154 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 159 NORTH AMERICA: LNP SERVICES MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 160 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 161 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 164 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 US: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 167 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 168 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 171 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 CANADA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 174 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 175 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 176 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 180 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 183 EUROPE: LNP SERVICES MARKET BY END USER, 2022-2029 (USD MILLION)
  • TABLE 184 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 185 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 188 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 190 GERMANY: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 191 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 192 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 193 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 194 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 195 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 UK: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 198 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 199 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 202 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 203 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 FRANCE: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 205 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 206 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 209 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 212 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 213 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 216 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 219 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 220 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 235 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2022-2029 (USD MILLION)
  • TABLE 236 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 237 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 240 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 243 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 244 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 247 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 248 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 249 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 250 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 251 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 254 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 255 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 256 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 257 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 258 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 264 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 265 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022-2029 (USD MILLION)
  • TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 271 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 272 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 278 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 279 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 280 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 282 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 287 LATIN AMERICA: LNP SERVICES MARKET BY END USER, 2022-2029 (USD MILLION)
  • TABLE 288 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 289 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 295 MEXICO: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 296 MEXICO: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 297 MEXICO: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 298 MEXICO: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 299 MEXICO: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 MEXICO: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 301 MEXICO: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 303 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 306 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 307 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 309 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 310 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 311 MIDDLE EAST: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 312 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 314 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 315 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 318 MIDDLE EAST: LNP SERVICES MARKET BY END USER, 2022-2029 (USD MILLION)
  • TABLE 319 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 320 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 322 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 323 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022-2029 (USD MILLION)
  • TABLE 324 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 325 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 326 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 327 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 328 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 329 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 330 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022-2029 (USD MILLION)
  • TABLE 331 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 332 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 333 AFRICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 334 AFRICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022-2029 (USD MILLION)
  • TABLE 335 AFRICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022-2029 (USD MILLION)
  • TABLE 336 AFRICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022-2029 (USD MILLION)
  • TABLE 337 AFRICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 338 AFRICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 AFRICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 340 AFRICA: LNP RAW MATERIALS MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 341 AFRICA: LNP SERVICES MARKET BY END USER, 2022-2029 (USD MILLION)
  • TABLE 342 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 343 LNP RAW MATERIALS MARKET: DEGREE OF COMPETITION
  • TABLE 344 LNP SERVICES MARKET: TOP SERVICE PROVIDERS (2023)
  • TABLE 345 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT FOOTPRINT
  • TABLE 346 LNP RAW MATERIALS & SERVICES MARKET: APPLICATION FOOTPRINT
  • TABLE 347 LNP RAW MATERIALS & SERVICES MARKET: SERVICE TYPE FOOTPRINT
  • TABLE 348 LNP RAW MATERIALS & SERVICES MARKET: REGION FOOTPRINT
  • TABLE 349 LNP RAW MATERIALS & SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 350 LNP RAW MATERIALS & SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 351 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2024
  • TABLE 352 LNP RAW MATERIALS & SERVICES MARKET: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 353 LNP RAW MATERIALS & SERVICES MARKET: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 354 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY OVERVIEW
  • TABLE 355 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCTS/SERVICES OFFERED
  • TABLE 356 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): DEALS, JANUARY 2021-JUNE 2024
  • TABLE 357 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 358 MERCK KGAA: PRODUCTS/SERVICES OFFERED
  • TABLE 359 MERCK KGAA: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 360 MERCK KGAA: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 361 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
  • TABLE 362 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES OFFERED
  • TABLE 363 EVONIK INDUSTRIES AG: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 364 NIPPON FINE CHEMICAL CO., LTD.: COMPANY OVERVIEW
  • TABLE 365 NIPPON FINE CHEMICAL CO., LTD.: PRODUCTS/SERVICES OFFERED
  • TABLE 366 NOF CORPORATION: COMPANY OVERVIEW
  • TABLE 367 NOF CORPORATION: PRODUCTS/SERVICES OFFERED
  • TABLE 368 NOF CORPORATION: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 369 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY OVERVIEW
  • TABLE 370 FUJIFILM PHARMACEUTICALS U.S.A., INC.: PRODUCTS/SERVICES OFFERED
  • TABLE 371 FUJIFILM PHARMACEUTICALS U.S.A., INC.: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 372 PRECISION NANOSYSTEMS: COMPANY OVERVIEW
  • TABLE 373 PRECISION NANOSYSTEMS: PRODUCTS/SERVICES OFFERED
  • TABLE 374 PRECISION NANOSYSTEMS: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2024
  • TABLE 375 PRECISION NANOSYSTEMS: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 376 PRECISION NANOSYSTEMS: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 377 RECIPHARM AB: COMPANY OVERVIEW
  • TABLE 378 RECIPHARM AB: PRODUCTS/SERVICES OFFERED
  • TABLE 379 RECIPHARM AB: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 380 EMERGENT: COMPANY OVERVIEW
  • TABLE 381 EMERGENT: PRODUCTS/SERVICES OFFERED
  • TABLE 382 EMERGENT: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 383 EUROAPI: COMPANY OVERVIEW
  • TABLE 384 EUROAPI: PRODUCTS/SERVICES OFFERED
  • TABLE 385 CAYMAN CHEMICAL: COMPANY OVERVIEW
  • TABLE 386 CAYMAN CHEMICAL: PRODUCTS/SERVICES OFFERED
  • TABLE 387 CORDENPHARMA: COMPANY OVERVIEW
  • TABLE 388 CORDENPHARMA: PRODUCTS/SERVICES OFFERED
  • TABLE 389 CORDENPHARMA: PRODUCT/SERVICE LAUNCHES, JANUARY 2021-JUNE 2024
  • TABLE 390 CORDENPHARMA: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 391 CORDENPHARMA: EXPANSIONS, JANUARY 2021-JUNE 2024
  • TABLE 392 GATTEFOSSE: COMPANY OVERVIEW
  • TABLE 393 GATTEFOSSE: PRODUCTS/SERVICES OFFERED
  • TABLE 394 ACUITAS THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 395 ACUITAS THERAPEUTICS: PRODUCTS/SERVICES OFFERED
  • TABLE 396 ACUITAS THERAPEUTICS: DEALS, JANUARY 2021-JUNE 2024
  • TABLE 397 IOI OLEO GMBH: COMPANY OVERVIEW
  • TABLE 398 IOI OLEO GMBH: PRODUCTS/SERVICES OFFERED

List of Figures

  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 3 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 4 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
  • FIGURE 5 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 6 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE SHARE ANALYSIS (2023)
  • FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
  • FIGURE 11 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 LNP RAW MATERIALS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 15 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 16 LNP RAW MATERIALS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 17 LNP RAW MATERIALS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 18 LNP SERVICES MARKET, BY SERVICE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 19 LNP SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 20 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 21 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES TO PROPEL LNP RAW MATERIALS MARKET
  • FIGURE 22 IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 23 JAPAN IS EXPECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 24 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 25 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 26 LNP RAW MATERIALS & SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR LNP RAW MATERIAL MANUFACTURERS
  • FIGURE 28 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
  • FIGURE 29 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
  • FIGURE 30 VALUE CHAIN ANALYSIS-MAXIMUM VALUE ADDED DURING FORMULATION DEVELOPMENT & MANUFACTURING PHASE
  • FIGURE 31 LNP RAW MATERIALS & SERVICES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR LIPID NANOPARTICLE PATENTS (JANUARY 2014-DECEMBER 2023)
  • FIGURE 33 LNP RAW MATERIALS & SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 34 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT
  • FIGURE 35 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2019-2023 (USD MILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET (2023)
  • FIGURE 38 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 39 LNP RAW MATERIALS & SERVICES MARKET: COMPANY FOOTPRINT
  • FIGURE 40 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 43 LNP RAW MATERIALS & SERVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2023)
  • FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2023)
  • FIGURE 46 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023)
  • FIGURE 47 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 NOF CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 49 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 RECIPHARM AB: COMPANY SNAPSHOT (2023)
  • FIGURE 51 EMERGENT: COMPANY SNAPSHOT (2023)
  • FIGURE 52 EUROAPI: COMPANY SNAPSHOT (2023)
  • FIGURE 53 IOI OLEO GMBH: COMPANY SNAPSHOT (2023)